Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Prostatic Neoplasms × Lapatinib × Clear all

Phase

Status

Completed 4 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 33 Neoplasm Metastasis 7 Neoplasms 4 Urinary Bladder Neoplasms 3 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Squamous Cell 2 Breast Neoplasms, Male 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Triple Negative Breast Neoplasms 1 Skin Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Metastatic Breast Cancer With Intracranial Metastases 1 Melanoma 1 Inflammatory Breast Neoplasms 1 Her2 Positive Metastatic Breast Cancer 1 Head and Neck Neoplasms 1 HER2 Positive Esophagogastric Cancer 1 GastroEsophageal Cancer 1 Esophageal Squamous Cell Carcinoma 1 Diarrhea 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Carcinoma, Ductal, Breast 1 Carcinoma 1 Breast Diseases 1 Brain Neoplasms 1

Interventions

Docetaxel 55 Prednisone 36 Leuprolide 24 enzalutamide 23 Abiraterone Acetate 19 bicalutamide 17 Magnetic Resonance Spectroscopy 17 Goserelin 15 Radiotherapy 14 abiraterone 12 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11 olaparib 9 Androgen Antagonists 9 cabazitaxel 8 Radiotherapy, Intensity-Modulated 8 Metformin 8 Ketoconazole 8 Gonadotropin-Releasing Hormone 8 Cyclophosphamide 8 gallium 68 PSMA-11 7 apalutamide 7 Doxorubicin 7 luprolide acetate gel depot 6 Radiosurgery 6 Estramustine 6 Dexamethasone 6 Calcitriol 6 pembrolizumab 5 cabozantinib 5 Zoledronic Acid 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00953576 2018-09-04

KHLAD

Dana-Farber Cancer Institute

Phase 1/2 Terminated

11 enrolled 9 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡